文献速递神经免疫

多发性硬化患者顺磁性边缘病灶演变与临床及影像学疾病进展的关联

Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-10-24

该研究基于前瞻性纵向队列,纳入160例多发性硬化患者和27名健康对照,评估顺磁性边缘病灶(PRL)消失与新发与临床残疾进展及脑萎缩的纵向关联。结果显示PRL消失率较高与确认的残疾进展(CDP)和独立于复发活动的进展(PIRA)年化率降低相关,新发PRL与PIRA年化率升高相关,但PRL演变与脑体积变化无关联。

要点

  • PRL消失率较高与CDP年化率降低相关(β均值=-0.262,95%CI -0.475至-0.049,q=0.028)。
  • PRL消失率较高与PIRA年化率降低相关(β均值=-0.283,95%CI -0.492至-0.073,q=0.036)。
  • 新发PRL与PIRA年化率升高相关(β均值=0.223,95%CI 0.049-0.398,q=0.036)。

核心结论

  • 现有PRL消失及无新发PRL与临床结局改善相关。
  • 这些发现进一步推动针对小胶质细胞介导的脑炎症的新疗法需求及预防新发PRL的临床策略。

研究设计与样本

  • 研究为前瞻性纵向队列研究,自布法罗大学 larger prospective, longitudinal cohort study 纳入受试者。
  • 纳入160例多发性硬化患者(73.8%女性;基线平均年龄46.6±11.4岁;基线平均病程13.8±10.6年;中位随访5.6年[四分位距5.2-7.8];26.9%为进展型MS)和27名健康对照(74.1%女性;基线平均年龄43.9±13.6岁;中位随访5.4年[5.2-5.6])。
  • 患者需有基线和随访时3T MRI及临床访视数据;有足够临床数据用于确认的残疾进展(CDP)分析者纳入残疾进展队列;有基线和随访脑容量数据者纳入脑萎缩队列。
  • PRL在基线和随访时评估,分为消失、新发或持续存在;采用线性模型比较年化PRL消失率或新发PRL(是/否)与年化CDP率、PIRA率或年化脑萎缩率,并校正基线PRL数量和随访时间等协变量。
  • 统计分析采用错误发现率(FDR;即q值)校正。

主要发现

  • PRL消失率较高与CDP年化率降低相关(β均值=-0.262,95%CI -0.475至-0.049,q=0.028)。
  • PRL消失率较高与PIRA年化率降低相关(β均值=-0.283,95%CI -0.492至-0.073,q=0.036)。
  • 新发PRL与PIRA年化率升高相关(β均值=0.223,95%CI 0.049-0.398,q=0.036)。
  • 新发PRL或PRL消失与脑体积变化无关联经FDR校正后仍无统计学意义(q>0.05)。

临床怎么用

  • 作者认为,现有PRL消失及无新发PRL与临床结局改善相关。
  • 作者认为,这些发现进一步推动针对小胶质细胞介导的脑炎症的新疗法需求及预防新发PRL的临床策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Recent technological advances have enabled visualizing in vivo a subset of chronic active brain lesions in persons with multiple sclerosis (pwMS), referred to as "paramagnetic rim lesions" (PRLs), with iron-sensitive MRI. PRLs predict future clinical disease progression, making them a promising clinical and translational imaging marker. However, it is unknown how disease progression is modified by PRL evolution (PRL disappearance, new PRL appearance). This is key to understanding MS pathophysiology and may help inform selection of sensitive endpoints for clinical trials targeting chronic active inflammation. To this end, we assessed the longitudinal associations between PRL disappearance and new PRL appearance and clinical disability progression and brain atrophy. METHODS: PwMS and healthy controls (HCs) were included from a larger prospective, longitudinal cohort study at the University at Buffalo if they had available 3T MRI and clinical visits at baseline and follow-up timepoints. PwMS with sufficient clinical data for confirmed disability progression (CDP) analysis were included in a Disability Progression Cohort, and pwMS and HCs with brain volumetry data at baseline and follow-up were included in MS and HC Brain Atrophy cohorts. PRLs were assessed at baseline and follow-up and assigned as disappearing, newly appearing, or persisting at follow-up. Linear models were fit to compare annualized PRL disappearance rates or new PRL appearance (yes/no) with annualized rates of CDP and progression independent of relapse activity (PIRA) or with annualized rates of brain atrophy, adjusting for covariates including baseline PRL number and follow-up time. Statistical analyses were corrected for false discovery rate (FDR; i.e., q-value). RESULTS: In total, 160 pwMS (73.8% female; mean baseline age 46.6 ± 11.4 years; mean baseline disease duration 13.8 ± 10.6 years; median follow-up time 5.6 [interquartile range 5.2-7.8] years; 26.9% progressive MS) and 27 HCs (74.1% female; mean baseline age 43.9 ± 13.6 years; median follow-up time 5.4 [5.2-5.6] years) were enrolled. Greater PRL disappearance rates were associated with reduced rates of CDP (β mean = -0.262, 95% CI -0.475 to -0.049, q = 0.028) and PIRA (β mean = -0.283, 95% CI -0.492 to -0.073, q = 0.036), and new PRL appearance was associated with increased rates of PIRA (β mean = 0.223, 95% CI 0.049-0.398, q = 0.036). By contrast, no associations between new PRL appearance or PRL disappearance and brain volume changes survived FDR correction (q > 0.05). DISCUSSION: Our results show that resolution of existing PRLs and lack of new PRLs are associated with improved clinical outcomes. These findings further motivate the need for novel therapies targeting microglia-mediated brain inflammation and adoption of clinical strategies to prevent appearance of new PRL.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Reeves JA, Bartnik A, Jakimovski D, et al. Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis. Neurology. 2024. PMID: 39447104. doi:10.1212/WNL.0000000000210004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。